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Abstract  
Mutations in either the mitochondrial or nuclear genomes are associated with a 
diverse group of human disorders characterized by impaired mitochondrial 
respiration. Within this group, an increasing number of mutations have been identified 
in nuclear genes involved in mitochondrial RNA metabolism, including ELAC2. The 
ELAC2 gene codes for the mitochondrial RNase Z, responsible for endonucleolytic 
cleavage of the 3’ ends of mitochondrial pre-tRNAs. Here, we report the 
identification of sixteen novel ELAC2 variants in individuals presenting with 
mitochondrial respiratory chain deficiency, hypertrophic cardiomyopathy and lactic 
acidosis. We provide evidence for the pathogenicity of the novel missense variants by 
studying the RNase Z activity in an in vitro system. We also modelled the residues 
affected by missense mutation in solved RNase Z structures, providing insight into 
enzyme structure and function. Finally, we show that primary fibroblasts from the 
affected individuals have elevated levels of unprocessed mitochondrial RNA 
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precursors. Our study thus broadly confirms the correlation of ELAC2 variants with 
severe infantile-onset forms of hypertrophic cardiomyopathy and mitochondrial 
respiratory chain dysfunction. One rare missense variant associated with the 
occurrence of prostate cancer (p.Arg781His) impairs the mitochondrial RNase Z 
activity of ELAC2, suggesting a functional link between tumorigenesis and 
mitochondrial RNA metabolism 
Key Words: Mitochondria, RNA, RNase Z, mitochondrial disease, cardiomyopathy 
1 | INTRODUCTION  
Mitochondria are essential for cell function through their involvement in ATP 
synthesis by oxidative phosphorylation (OXPHOS), and host a number of other 
biosynthetic pathways. Whereas the majority of the mitochondrial proteome is 
encoded in the cell nucleus and imported into the mitochondria following synthesis on 
cytosolic ribosomes, 13 essential subunits of the OXPHOS system are synthesised 
within the organelle. For this reason, mitochondria maintain and express 
mitochondrial DNA (mtDNA) that encodes the aforementioned polypeptides, together 
with the mitochondrial (mt-) tRNAs and rRNAs. All remaining protein components of 
the mitochondrial gene maintenance and expression machinery such as proteins 
responsible for mtDNA transcription, precursor RNA processing enzymes, the 
mitoribosomal proteins, mitochondrial aminoacyl tRNA synthetases and others are 
encoded by the nuclear genes (Hallberg & Larsson, 2014; Rorbach & Minczuk, 
2012). More than 50 nuclear-encoded mitochondrial proteins involved in 
mitochondrial gene expression are linked to heritable disorders (Frazier, Thorburn, & 
Compton, 2017; Powell, Nicholls, & Minczuk, 2015; Rahman & Rahman, 2018; 
Stenton & Prokisch, 2018; Van Haute et al., 2015). 
Human mt-mRNAs, mt-tRNAs, and mt-rRNAs are transcribed as part of large 
polycistronic precursor transcripts encoded by the 16.6 kb mtDNA. The 
mitochondrial gene sequences for mt-rRNA and, in the majority of cases, mt-mRNA 
are separated by mt-tRNA sequences, leading to the proposed ‘tRNA punctuation’ 
model of RNA processing (Anderson et al., 1981; Ojala, Montoya, & Attardi, 1981). 
Processing of the intervening mt-tRNAs generates individual mt-mRNAs and mt-
rRNAs. In human mitochondria, endonucleolytic cleavage at the 5′ and 3′ termini of 
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mt-tRNAs is performed by the RNase P complex (Holzmann et al., 2008) and the 
RNase Z activity of ELAC2, respectively (Brzezniak, Bijata, Szczesny, & Stepien, 
2011; Rossmanith, 2011). Two human nuclear genes encode orthologues of the 
bacterial RNase Z (elaC): ELAC1 (MIM# 608079, RefSeq: NM_0018696.2, 
NP_061166.1) and ELAC2 (MIM# 605367, RefSeq: NM_018127.6, NP_060597.4). 
The ELAC1 gene encodes a short form of RNase Z (also referred to as RNase ZS) that 
is located in the cytosol, but its function in humans is unknown (Rossmanith, 2011). 
ELAC2 codes for a long form of RNase Z (also referred to as RNase ZL). Alternative 
translation initiation of ELAC2 mRNA has been proposed to produce two ELAC2 
protein isoforms; one targeted to the mitochondria, the other to the nucleus. 
Translation of the longer isoform initiates at the methionine codon 1 (M1) and the 
first 31 amino acids of this isoform are predicted to contain a mitochondrial targeting 
sequence (MTS) (Rossmanith, 2011). This longer isoform of ELAC2 has a well-
characterized role in mitochondrial pre-tRNA processing (Brzezniak et al., 2011; 
Dubrovsky, Dubrovskaya, Levinger, Schiffer, & Marchfelder, 2004; Lopez Sanchez 
et al., 2011; Rossmanith, 2011). If translation is initiated at the methionine codon 16 
(M16) (relative to the longer mitochondrially-targeted form) ELAC2 is targeted to the 
nucleus. Recent data on the activity of ELAC2 in vivo, generated using a knockout 
mouse model, revealed that it has a non-redundant role in the processing of mtDNA-
encoded tRNAs and that it contributes to the processing of nuclear-encoded tRNA, 
miRNA and C/D box snoRNAs (Siira et al., 2018).  
Thus far, seven different pathogenic mutations have been reported in ELAC2-
associated mitochondrial dysfunction. In our previous work, we investigated the 
functional consequences of ELAC2 variants in patients presenting with a recessively 
inherited form of hypertrophic cardiomyopathy (HCM), hypotonia, lactic acidosis, 
and failure to thrive (Haack et al., 2013). This previous work identified a total of four 
disease alleles (coding for p.Phe154Leu, p.Arg211*, p.Leu423Phe and p.Thr520Ile) 
in three families. One of these, the variant coding for p.Phe154Leu, was also recently 
reported as prevalent in consanguineous Arabian families affected by infantile 
cardiomyopathy (Shinwari et al., 2017). In contrast, a homozygous splice site 
mutation (c.1423+2T>A) in ELAC2 has been associated with developmental delay 
and minimal cardiac involvement in a consanguineous Pakistani family (Akawi et al., 
2016). A single heterozygous ELAC2 variant coding for p.Pro32Arg was recently 
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reported in an infant presenting with encephalopathy, epilepsy, and growth and 
developmental retardation (Kim, Kim, Lee, & Cheon, 2017). The patient also 
developed Tetralogy of Fallot, however, without evidence of cardiomyopathy. Since 
the transmission pattern of ELAC2-related disease in the families reported previously 
(Akawi et al., 2016; Haack et al., 2013; Shinwari et al., 2017) was consistent with 
recessive inheritance, the relevance of this variant remains unclear. Finally, an 
Assyrian patient presenting with chorea, psychosis, acanthocytosis, and displaying a 
prolonged survival has been identified to carry compound heterozygous ELAC2 
variants coding for p.Gly132Arg and p.Ser347Phe. The patient had a mild cardiac 
hypertrophy without evidence of pump failure. Muscle biopsy did not indicate any 
evidence of respiratory chain defect, despite of the presence of cytochrome oxidase 
(COX)–negative and ragged-red fibers (Paucar et al., 2018).  
In the present work, we report the identification of sixteen additional ELAC2 variants 
(ten missense, two frameshift and four splice mutations) in individuals who present 
with mitochondrial respiratory chain deficiency, HCM and lactic acidosis. We 
provide further evidence for the pathogenicity of the two previously reported and new 
evidence for eight newly identified missense variants by studying the RNase Z 
activity in an in vitro system. Fibroblasts from the individuals with novel ELAC2 
variants showed elevated levels of unprocessed mt-tRNA precursors. The 
combination of in vitro ELAC2 activity and mtRNA processing analysis provided the 
pathogenicity evidence for all patients harboring the previously unreported ELAC2 
variants. Moreover, modelling of the missense substitutions provided additional 
insight into the effects of substitutions on enzyme structure. 
2 | MATERIALS AND METHODS  
2.1 | Ethics statement 
Informed consent for diagnostic and research-based studies was obtained for all 
subjects in accordance with the Declaration of Helsinki protocols and approved by 
local institutional review boards. 
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2.2 | Exome Sequencing, variant prioritization, reevaluation and verification  
For reevaluation of the ELAC2 variants in P1 (previously reported as patient 27 in 
(Taylor et al., 2014)) and also for the analysis of the ELAC2 splice variants in P6 and 
P8, RNA purification from fibroblasts and cDNA retrotranscription was used to verify 
the identified variants, we used RNeasy mini kit (QIAGEN) and GoTaq 2-Step 
RTqPCR System (Promega), respectively, according to the manufacturers’ protocols. 
Primers used for cDNA amplification are available upon request. 
For P2 and P10-P13 exome sequencing and variant prioritisation was performed by 
commercial laboratories: P2 - Fulgent Diagnostics, P10 and P12 - Baylor College of 
Medicine, Human Genome Sequencing Center, P11- Centogene, as described in 
previously (Trujillano et al., 2017) and P13 – UCL. 
For P3, targeted NGS sequencing using a custom Ampliseq panel targeting 55 
mitochondrial translation genes (IAD62266) and subsequent Ion Torrent PGM 
sequencing was performed essentially as described previously (Alston et al., 2016). 
Candidate gene sequencing was performed for all coding exons of the ELAC2 gene 
(including intron-exon boundaries) using M13-tagged amplicons and BigDye v3.1 
sequencing kit (Life Technologies). Capillary electrophoresis was performed using an 
ABI3130xl (Life Technologies). NGS variant confirmation was performed by Sanger 
sequencing using oligonucleotides targeting the exons of interest.  
For P4 and P8, genomic DNA from the individuals and their parents was isolated 
from whole blood using the chemagic DNA Blood Kit special 
(PerkinElmer,Waltham, USA), according to the manufacturer’s protocol. Exome 
sequencing was performed as previously described (Kremer et al., 2017). Exonic 
regions were enriched using the SureSelect Human All Exon kit (50Mb_v5) from 
Agilent followed by sequencing as 100 bp paired-end runs on an Illumina HiSeq. 
2500. Reads were aligned to the human reference genome (UCSC Genome Browser 
build hg19) using Burrows-Wheeler Aligner (v.0.7.5a). Identification of single-
nucleotide variants and small insertions and deletions (indels) was performed with 
SAMtools (version 0.1.19). For analysis of rare bi-allelic variants, only variants with 
a minor allele frequency (MAF) of less than 1% in our internal Munich database of 
14,000 exomes were considered. 
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For P5, WES was undertaken using previously described methodologies and 
bioinformatics variant filtering pipelines (Bonnen et al., 2013) 
For P6 and P9 a targeted custom panel (Nextera rapid capture, Illumina) containing 
genes responsible for mitochondrial disorders was used (Ardissone et al., 2018). 
Variant filtering was performed as described in Legati et al. (Legati et al., 2016).  
For P7, exome capture and massively parallel sequencing were outsourced (BGI, 
Shenzhen, China) using Sure Select Human All Exon V.4 Agilent and deep Illumina 
HiSeq technology (median reads depth = 50×). High quality variants were filtered 
against public (dbSNP146 and EXAC V.0.3) and in-house database, to retain private, 
rare (MAF less than 1%) and clinically pathogenic nucleotide changes. Variants 
prioritisation in the context of their functional impact was performed using in silico 
programs for missense mutations (Sift and Poliphen2) and also taking into account 
changes potentially affecting splice sites. All variants identified by NGS were 
validated by Sanger Sequencing as well the segregation in the family.  
2.3 | RNA isolation and RNA northern blotting 
RNA extraction and northern blotting were performed essentially as described 
previously (Pearce, Rorbach, et al., 2017). Briefly, RNA was extracted from cells at 
60 - 80 % confluency using TRIzol reagent (Ambion), following the manufacturer's 
instructions. Gels run on the Bio-Rad Mini-Sub Cell GT were used for the separation 
of RNA samples (5 μg per sample) for northern blotting. A half volume of Gel 
Loading Buffer II (Ambion) was added to samples before heating at 55 °C for 10 
minutes, chilled on ice for 2 minutes, and then loaded onto a 1.2 % Agarose gel (1 x 
MOPS, 0.7 M formaldehyde). Electrophoresis was carried out at 4 °C in 1 x MOPS, 
0.3 M formaldehyde and 10 μg/mL ethidium bromide. Gels were semi-dry blotted 
onto a positively charged nylon membrane (Hybond-N+, GE Healthcare) for >12 
hours, after which the membrane was cross-linked and hybridized with [32P] labelled 
antisense RNA probes as described previously (Rorbach et al., 2014). 
2.4 | Recombinant protein purification and mutagenesis  
Wild type and mutant ELAC2 proteins (GenBank Accession number: NM_018127.6) were expressed 
from Gly50 to Gln826 using the baculovirus system and insect SF9 cells, and affinity purified as 
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
previously described (Yan, Zareen, & Levinger, 2006). Missense mutants were constructed by overlap 
extension PCR. Subcloning sites used for substitutions in the amino domain and linker were introduced 
from the BamHI site at the amino end to the internal natural EcoRI site (nt 1450 in NM_018127) and in 
the carboxy domain from the EcoRI site to the introduced XhoI site following the termination codon. 
Sequences of the mutant constructs were confirmed by Sanger sequencing (Macrogen). 
2.5 | RNase Z processing experiments 
The mitochondrial pre-tRNA substrates for RNase Z reactions were prepared by runoff T7 
transcription using cis-acting hammerheads to cleave at +1. The mt-tRNALeu(UUR) substrate has a 29 nt 
3’-end trailer with natural sequence ending with a SmaI runoff (-CCC) and mt-tRNAIle has a 19 nt 3’-
trailer, also ending with a SmaI runoff. Substrate 5’ ends were radiolabelled using [γ-32P]-ATP and 
polynucleotide kinase. For processing experiments, the concentration of unlabelled substrate was 
varied, over the range from 4 – 100 nM, at a constant much lower concentration of labelled substrate 
used as a tracer. The enzyme was used at the lowest concentration that produces a quantifiable product 
band at the highest concentration of unlabelled substrate used in the experiment. Kinetic experiments 
were performed with wild type enzyme at 10 pM using mt-tRNALeu(UUR) substrate, and at 50 pM using 
mt-tRNAIle, as in previous experiments (Levinger & Serjanov, 2012). Mutant enzymes were used at a 
higher concentration than wild type depending on the impairment factor (Supp. Figure S1). Variant 
processing experiments were performed in parallel with wild-type on the same day. Reactions were 
performed using Processing Buffer (PB) consisting of 25 mM Tris-Cl pH 7.2, 1.5 mM CaCl2, 1 mM 
freshly prepared dithiothreitol and 0.1 mg/ml BSA. The reason for the use of CaCl2, as opposed to e.g. 
MgCl2, is related to the mitochondrial concentration of Ca2+, which is higher than that of Mg2+ (Thiers 
& Vallee, 1957), with our previous studies indicating higher ELAC2 processing activity on mt-tRNA 
precursors on the presence of Ca2+ (Yan et al., 2006). Reactions were sampled after 5, 10 and 15 min 
incubation at 37 oC, electrophoresed on denaturing 6% polyacrylamide gels and images were obtained 
from dried gels using a storage phosphor screen and Typhoon scanner and analysed with ImageQuant 
TL (GE Life Sciences). In this design with constant trace labelled substrate and varying concentration 
of unlabelled substrate the measurement of proportion of product per minute of reaction is equivalent 
to V/[S]. V is obtained by multiplying by [unlabelled S] for each reaction, as illustrated in the 
processing data figures. 
2.6 | In silico modelling  
The recently published structure of Saccharomyces cerevisiae RNase Z (PDB 5MTZ (Ma et al., 2017)) 
was used to model the position and function of residues at which substitutions were observed in this 
study. Molecular structures were displayed using PyMOL. The overall structure is shown using cartoon 
and individual residues with sticks, polar contacts with dashed lines and hydrophobic residues with 
dots. The active site and regions proximal to it, which directly contact the substrate, are found in the 
carboxy domain of ELAC2 (a long form RNase Z, RNase ZL), and were superimposed onto the 
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corresponding regions in the only available co-crystal structure of RNase Z with pre-tRNA substrate, 
from Bacillus subtilis (PDB 4GCW) (Pellegrini, Li de la Sierra-Gallay, Piton, Gilet, & Condon, 2012).  
3 | RESULTS  
3.1 | Summary of clinical features of the investigated patient cohort. 
We investigated 13 families with a cohort of 13 infants, most presenting with early-
onset, syndromic cardiomyopathy, with hypertrophic cardiomyopathy (HCM) being 
present in 10 subjects, dilated cardiomyopathy (DCM) in 2 subjects and one subject 
being reported without any cardiac problems. All subjects with the exception of P10 
also presented with lactic acidosis. These clinical features raised suspicion of 
mitochondrial disease. Indeed, a biochemical defect of the mitochondrial respiratory 
chain (MRC) complexes was detected in all investigated subjects (n=10), with 
isolated Complex I deficiency prevailing in most of the patients (7/10) and the 
remaining subjects presenting with combined MRC deficiencies. The onset of 
symptoms was either from birth (P1, P2 and P11), neonatal (P5), infantile (P4, P6-
P10, P12 and P13) or early childhood (P3). Most of the patients also displayed 
developmental delay. Evidence of brain involvement was found in P2 and P9. P7 and 
P10 were successfully treated by heart transplantation at age 3.8 years and 10 months, 
respectively (Parikh et al., 2016; Santorelli et al., 2002), whereas P12 underwent two 
failed cardiac transplants. The summary of genetic, biochemical, and clinical findings 
of all individuals is provided in Table 1. Pedigrees of investigated families and 
detailed case reports are provided in the Supp. Material. 
3.2 | Identification of ELAC2 variants 
Using whole exome sequencing (WES) or targeted, panel-based next-generation 
sequencing, we screened a group of patients presenting with MRC deficiencies and 
cardiomyopathy (Table 1). Three of the analyzed patients (P5, P11 and P13) harbored 
the previously described homozygous c.460T>C (p.Phe154Leu) ELAC2 variant 
(Haack et al., 2013; Shinwari et al., 2017). All remaining patients of the analyzed 
cohort harbored novel missense (n=10), frameshift (n=2) or splice site (n=4) 
mutations (Figure 1 and Table 1). P2 harbored a novel consensus splice variant 
(c.1423+1G>A) in the same splice site as previously reported patients of Pakistani 
origin (c.1423+2T>A) (Akawi et al., 2016). All these variants were extremely rare or 
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not reported in public databases and predicted damaging using Polyphen-2 (Adzhubei 
et al., 2010).  
Of note, P1 was previously included in WES analysis based on multiple MRC 
complex deficiency together with a cohort of 53 patients (patient 27) (Taylor et al., 
2014). This previous study identified heterozygous c.1478C>T (p.Pro493Leu) and 
c.1621G>A (p.Ala541Thr) ELAC2 variants and predicted them to be pathogenic. Re-
evaluation of the c.1621G>A (p.Ala541Thr) variant revealed a minor allele frequency 
of 3.4% in the gnomAD database, with 218 homozygote individuals, which precludes 
pathogenicity and prompted analysis of cDNA obtained from P1 fibroblasts; this 
revealed that the c.1478C>T (p.Pro493Leu) and c.1621G>A (p.Ala541Thr) variants 
are situated in cis. Further, analysis of the cDNA sequence revealed a heterozygous 
change c.202C>T (p.Arg68Trp), which was absent in the gnomAD database and 
affects a moderately conserved amino acid. The c.202C>T substitution, located in a 
region which was not covered by the previous WES, was confirmed also in genomic 
DNA of P1.  
ELAC2 transcript analysis performed in the other two patients with splice site variants 
confirmed their deleterious effects. In P6 (compound heterozygous c.1690C>A; 
c.798-1G>T), we found mono-allelic expression of c.1690A, and no aberrant species, 
indicating that the splice variant causes mRNA decay. In P8 (compound heterozygous 
c.245+2T>A; c.1264C>G) we amplified two species of ELAC2 transcripts: the full-
length and one missing exon 1. 
3.3 | In vitro RNase Z activity of mutant ELAC2 enzymes 
Despite the increased utility of genetic testing, providing proof of pathogenicity of 
novel variants remains challenging and follow up functional studies in vitro should 
therefore be included as an integral part of the evaluation. In order to provide 
evidence for the pathogenicity of identified ELAC2 variants, we set out to study the 
RNase Z activity of the enzyme in the presence of the missense substitutions or the 
truncating variants resulting from frameshift mutations. Substitutions were introduced 
into the human ELAC2 cDNA (Genbank Acc# NM_018127.6) and the mutant 
proteins were expressed in baculovirus using insect SF9 cells (Saoura, Pinnock, 
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Pujantell-Graell, & Levinger, 2017). Affinity-purified recombinant mutant proteins 
were tested using precursor mt-tRNALeuUUR or mt-tRNAIle as substrates.  
In order to assess the utility of the in vitro system to evaluate the pathogenicity of the 
novel ELAC2 variants, we first tested the three previously reported missense 
mutations (p.Phe154Leu, p.Leu423Phe, p.Thr520Ile), that have been extensively 
characterized in terms of pathogenicity in our previous paper (Haack et al., 2013). 
Recombinant mutant proteins expressed well (Supp. Figure S1a), suggesting that the 
substitutions do not severely alter stability of ELAC2. Next, we obtained Michaelis-
Menten plots and kinetic parameters in comparative kinetic experiments testing 
endonucleolytic cleavage of mitochondrial pre-tRNA using wild-type and mutant 
ELAC2 preparations (Table 2, Figure 2a and Supp. Figure S1b-c). Two of three 
mutants tested showed significant impairment of the RNAse Z activity, exhibiting 
reduced kcat/KM values as compared to the wild-type enzyme (Figure 2a). The 
impairment observed for the mutant proteins was largely due to reduced kcat. In these 
two instances the impairment is moderate, with kcat/KM being in the range of 20–80% 
of the WT enzyme, consistent with the essential role of ELAC2 in mt-tRNA 
processing. This result further confirms the pathogenicity of the p.Phe154Leu and 
p.Thr520Ile variants. The lack of statistically significant impairment of pre-tRNA 
processing by p.Leu423Phe is inconsistent with the previously reported defect of 
mtRNA processing in primary fibroblasts derived from the patient with the 
p.Leu423Phe coding variants (Haack et al., 2013). Of note, the effects of 
p.Leu423Phe in fibroblasts were less pronounced as compared to those observed for 
the patient cells carrying the homozygous p.Phe154Leu mutation or for cells 
harboring a missense mutation p.Thr520Ile (compound heterozygous with a stop 
mutation p.Arg211∗). The latter may suggest a relatively mild impairment of the 
ELAC2 activity by p.Leu423Phe.  
Next, we expressed and tested 10 novel missense variants detected in our patients 
using pre-mt-tRNALeu(UUR) as a substrate (Table 3, Figure 2b). A severe reduction of 
kcat/KM values (below 20% of the wild type, WT, enzyme) was observed for 
p.Pro493Leu, p.Tyr729Cys, p.His749Tyr and p.Arg781His. Moderate impairment of 
the kcat/KM values (20-80% of the WT enzyme) was observed for p.Arg68Trp, 
p.Gln388Arg, p.Leu422Val and p.Lys660Ile. The kcat/KM values for p.Arg564Ser and 
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p.Ala680Val were not significantly affected for the pre-mt-tRNALeu(UUR) substrate. 
Reduced kcat is principally responsible for impairment of mutant enzymes, however, a 
substantial increase in KM relative to WT was observed for p.Arg781His; additionally 
the p.Pro493Leu and p.Tyr729Cys mutants exhibited lesser increases in KM (Table 3). 
Previous data from RNASeq and northern blots indicated junction-dependent 
impairment of endonucleolytic cleavage of pre-tRNA by mutant ELAC2 enzymes 
(Haack et al., 2013). With this in mind, we tested the p.Arg564Ser mutant (which did 
not show detectable impairment with the pre-mt-tRNALeu(UUR)) using a different 
substrate, pre-mt-tRNAIle. Moderate, however not statistically significant, impairment 
of the kcat/KM values ratios (in the range of 20-80% of the WT enzyme) was observed 
for p.Arg564Ser with the pre-mt-tRNAIle substrate (Figure 2c, Table 4).  
Two novel frameshift variants were detected in our patient cohort: p.Ile153Tyrfs*6 
and p.Cys670Serfs*14, both resulting in premature stop codons (Table 1). The 
p.Ile153Tyrfs*6 mutation results in early truncation of the ELAC2 protein, 
eliminating all functional motifs, and was therefore considered a priori as loss of 
function; expression and assay of this mutant was not attempted. On the other hand, 
p.Cys670Serfs*14 occurs closer to the carboxy terminus. We therefore tested 
p.Cys670Ser*14 for enzymatic activity. This mutant expressed poorly, however, and 
displayed no detectable enzyme activity, confirming the functional importance of 
domains beyond the truncation, including motif V and other functional elements 
(Supp. Figure S3). Taken together, the analysis of recombinant mutant proteins 
indicates that, in most cases, the detected ELAC2 variants impair the RNase Z 
activity, consistent with pathogenicity. However, due to certain limitations of the in 
vitro assay used, for example precursor substrate specificity, the use of substrates 
without post-transcriptional nucleotide modifications, or not taking into account a 
potential effect of a particular variant on protein stability in living cells, orthogonal 
functional studies are necessary to support the pathogenic nature of the detected 
variants. 
3.4 | Analysis of mtRNA processing in primary fibroblasts from affected individuals 
In the polycistronic transcripts produced through transcription of mtDNA, the two mt-
rRNAs and most mt-mRNAs are punctuated by one or more mt-tRNAs. As shown 
previously, impairment in the ELAC2 endonucleolytic activity results in the presence 
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of 3’ unprocessed mt-tRNAs, containing mt-rRNA or mt-mRNA extensions (Haack et 
al., 2013; R. Kopajtich, Mayr, & Prokisch, 2017). To analyze the levels of 
unprocessed mt-tRNAs resulting from impaired RNase Z activity of ELAC2, we used 
northern blotting with RNA samples isolated from fibroblasts of all patients that 
harbored novel ELAC2 mutations. P5, P11 and P13 were excluded from this analysis 
as these three individuals harbored the previously characterized c.460T>C 
(p.Phe154Leu) variant in homozygosity (Haack et al., 2013). In RNA samples from 
P1-P4, P6-P10 and P12, we found substantially increased amounts of 3′ end 
unprocessed mt-tRNA precursors at the cleavage sites of mt-tRNAVal-16S rRNA, mt-
tRNAMet-ND2 (Figure 3) and mt-tRNALeu(UUR)-ND1 (Supp. Figure S2) as compared 
to the control cell lines. This analysis further showed that RNA samples from the 
patients that were compound heterozygous for c.1690C>A (p.Arg564Ser) or 
c.2039C>T (p.Ala680Val) (P6 or P7, respectively) – the two mutations that exhibited 
little impairment with the pre-mt-tRNALeu(UUR) substrate in the in vitro experiments 
(Figure 2b) - accumulated unprocessed mt-tRNALeu(UUR)-ND1 junctions. This latter 
result confirms the causal role of the p.Arg564Ser and p.Ala680Val substitutions.  
Assessing the clinical significance of sequence variants that may alter splicing, 
especially in the context of tissue-specific disease manifestation, can be challenging 
(Spurdle et al., 2008). In four patients from our cohort, P2, P3, P6 and P8, compound 
heterozygous splice-site mutations were present. The analysis of the processing of 
mtRNA of these four patients revealed accumulation of unprocessed mitochondrial 
tRNA-rRNA or tRNA-mRNA junctions, providing evidence for the disruptive nature 
of the detected splice variants. Taken together, the observed defect in the processing 
of mt-tRNA junctions in the patient-derived cell lines provides additional evidence for 
the pathogenicity of all detected, novel missense, frameshift and splice site ELAC2 
variants.  
3.5| In silico characterization of mutations in ELAC2 
Having established the damaging nature of the detected ELAC2 missense mutations 
both in vitro and in living cells, we set out to develop a rationale for the observed 
biochemical impairment, as summarized in Table S1. To this end, we modelled all 13 
substitutions (3 published previously and 10 novel) into the structure of S. cerevisiae 
RNase Z (Trz1) (PDB 5MTZ (Ma et al., 2017)). Analysis of the ELAC2 structure 
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indicates that the amino and carboxy domains arose from a duplication, with the 
active site being retained in the carboxy domain and the flexible arm being preserved 
in the amino domain (Schilling et al., 2005). The amino and carboxy domains are 
tethered by a flexible linker (Supp. Figure S3). Substitutions at Arg68, Phe154, 
Gln388 are found in the amino domain, Leu422 and Leu423 are in the linker domain 
(flexible tether), whereas Pro493, Thr520, Arg564, Lys660, Arg680, Tyr729, His749, 
Arg781 are located in the carboxy domain of ELAC2 (Figure 4 and Supp. Figure 
S3).  
Using the Trz1 structure, we have modelled the residues Arg68, Phe154 and Gln388 
in the amino domain in which substitutions were found associated with HCM. 
Modelling using the Trz1 structure is less obviously effective in cases where the 
residues in the S. cerevisiae Trz1 sequence are not conserved (Supp. Figure S3); in 
these cases, however, the overall sequence similarity in the region suggests structural 
relationships of inferred secondary structure elements. All three residues are located 
close to the domain interface. The modelling of Arg68 and Gln388 suggests the 
substitutions at these sites could disrupt the structure and folding of ELAC2 through 
their indirect effects on a number of polar contacts across the amino- and carboxy 
domain interface (Supp. Figure S4). Phe154 is conserved and aligns with Trz1 
Phe103 (Supp. Figure S3). Across the N- and C-domain interface Phe154 closely 
approaches the motif II region, suggesting that reducing the size of the hydrophobic 
side chain in the case of p.Phe154Leu could affect packing of a region which is 
critical for metal ion binding and catalysis (Supp. Figure S5). 
Contiguous residues Leu422 and Leu423 are located in the linker domain of the 
human ELAC2 at the apex of the loop between two twisted beta sheets in the amino 
domain. Substitutions at these positions may affect the structure due to subtle changes 
in regional hydrophobicity (Supp. Figure S6).  
We next set out to model residues in the carboxy domain (Pro493, Thr520, Arg564, 
Lys660, Ala680, Tyr729, His749 and Arg781). All of these but two could be 
effectively modelled using Trz1. However, it was advantageous to model Pro493 and 
Tyr729 using the Bacillus subtilis (Bsu) enzyme-substrate complex structure (PDB 
4GCW, (Pellegrini et al., 2012)). The conserved residue Pro493 is close to Lys495 
and similarly, Tyr729 is next to Arg728; equivalent residues in B. subtilis RNase Z 
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Lys15 and Arg273, respectively, make polar contacts with the substrate on both sides 
of the acceptor stem (Figure 5). The interpretation of the model suggests that 
Pro493Leu impairs RNase Z activity by changing the fold of the PxKxRN loop, 
interfering with the polar contact between Lys495 and the backbone of substrate 
nucleotides +1 and +2 on the 5’ side of the tRNA acceptor stem. Correspondingly, 
substitution of Tyr729 with Cys could alter the fold of the motif V loop, interfering 
with contacts between the positively charged side chain of Arg728 and the substrate 
in the backbone of nucleotides 71, 72 and 73 on the 3’ side of the tRNA acceptor stem 
of the pre-tRNA substrate. In the wild type enzyme, the two basic residues, Lys495 
and Arg728, clamp the substrate close to the scissile bond from both sides (Figure 5). 
This interpretation of in silico modelling is partially consistent with the kinetic 
experiments, in which the p.Pro493Leu and p.Tyr729Cys mutants display the greatest 
impairment factors of any patient-related substitutions analysed so far.  
Thr520 (Thr513 in the Trz1 structure) is a highly conserved motif I residue. A charge 
relay system links the motif I aspartate (Asp515) with the first histidine of motif II 
(His546). The model implies that subtle regional changes impair catalysis, transmitted 
to motif I (Supp. Figure S7).  
Arg564 is not conserved, and is located in the long, overall poorly conserved region 
between motifs II and III, with no significant polar or hydrophobic contacts in this 
region of the Trz1 structure (Supp. Figure S3). The mutated residue is reasonably 
close to motif II, implying that subtle regional changes may impair catalysis when 
transmitted to this motif. 
The side chain of conserved Lys660 (Lys693 in the Trz1 structure) found in 𝛃𝛃24 is 
predicted to make polar contacts with the backbone of the preceding residues within 
12 residues of the motif IV aspartate (Supp. Figure S4 and S8). Loss of these side 
chain-specific polar contacts with the p.Lys660Ala substitution could therefore affect 
the position of Asp666, the motif IV aspartate, which is critical for metal ion binding 
and catalysis (Supp. Figure S8B). Similarly, Ala680 (Ser715 in the Trz1 structure) 
located below the base of 𝛃𝛃25 could, when replaced by the bulkier valine in the case 
of the Ala680Val mutation, indirectly affects the location of the Motif IV aspartate 
(Supp. Figure S8B). Finally, His749 (Ser787 in the Trz1 structure), is predicted to be 
contiguous with the aspartate in the AxD loop and substitution at this position could 
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perturb that residue. The AxD loop is conserved and the aspartate in this loop makes 
polar contacts with the backbone of a conserved leucine at the start and a conserved 
asparagine at the end of the PxKxRN loop (Supp. Figure S8B; cf (Wang et al., 
2012)).  
The Arg781 residue is present on a long C-terminal α-helix. Although this residue is 
not conserved, the region where it is found is generally highly polar. In metazoan 
ELAC2 enzymes this region consists of frequently interspersed acidic and basic 
residues while in Saccharomyces cerevisiae it is principally acidic (Supp. Figure S3). 
In S. cerevisiae RNase Z, the long α-helix is curved and approaches the predicted 
location where the substrate acceptor stem is clamped by polar contacts between 
Lys495 of the PxKxRN loop and nt +1-2 of the pre-tRNA substrate and between 
Arg728 of the motif V loop and nt 71-72-73 of the substrate (Figure 5 and Supp. 
Figure S9). The region where Arg781 is found could thus modulate both substrate 
binding and catalysis, consistent with impairment of the p.Arg781His mutant which 
arises from the combination of a reduction in kcat and increased KM, (Table 3 and 
Table 4). 
4 | DISCUSSION  
The mitochondrial genome encodes key subunits of the OXPHOS system and RNA 
components needed for mitochondrial translation, with nuclear genes encoding the 
proteins responsible for mtDNA transcription, post-transcriptional RNA processing 
and translation. Recent years have seen a rapid development in our understanding of 
these machineries both in human health and in disease state (Pearce, Rebelo-Guiomar, 
et al., 2017; Rebelo-Guiomar, Powell, Van Haute, & Minczuk, 2019). Dysfunction of 
mitochondrial gene expression, caused by mutations in either the mitochondrial or 
nuclear genomes, is associated with a diverse group of human disorders characterized 
by impaired mitochondrial respiration. Within this group, an increasing number of 
mutations have been identified in nuclear genes involved in endonucleolytic 
processing of precursor mtRNA (Deutschmann et al., 2014; Haack et al., 2013; 
Metodiev et al., 2016) and in mtRNA epitranscriptome shaping (Bykhovskaya, Casas, 
Mengesha, Inbal, & Fischel-Ghodsian, 2004; Chakraborty et al., 2014; Garone et al., 
2017; Ghezzi et al., 2012; Robert Kopajtich et al., 2014; Nicholls, Rorbach, & 
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Minczuk, 2013; Powell, Kopajtich, et al., 2015; Van Haute et al., 2016; Wedatilake et 
al., 2016; Yarham et al., 2014; Zeharia et al., 2009).  
4.1 | Genotype-phenotype correlation  
Clinical syndromes associated with defects in mtRNA metabolism are characterized 
by the variable combination of encephalopathy, myopathy, sideroblastic anemia, 
cardiomyopathy, hearing loss, optic atrophy, and renal or liver dysfunction 
(Boczonadi, Ricci, & Horvath, 2018; D'Souza & Minczuk, 2018). Hypertrophic 
cardiomyopathy and lactic acidosis are frequent presentations in some mitochondrial 
diseases related to dysfunctional mt-tRNA maturation, such as those caused by 
biallelic variants in MTO1 (MIM# 614667), GTPBP3 (MIM# 608536), AARS2 
(MIM# 612035) and RARS2 (MIM# 611524.)(Ghezzi et al., 2012; Gotz et al., 2011; 
Robert Kopajtich et al., 2014; Lax et al., 2015). With multiple novel variants in 
ELAC2, our study further underscores HCM as a manifestation of dysfunctional 
mitochondrial gene expression. Moreover, it indicates a strong relationship between a 
confirmed molecular diagnosis of ELAC2-related mitochondrial disease and the key 
clinical phenotypes (hypertrophic cardiomyopathy, multiple respiratory chain defects 
and lactic acidosis) for the majority of variants detected. However, one case (P2), who 
harbors a c.1423+1G>A ELAC2 variant affecting a consensus splice site (in 
compound heterozygosity with a truncating c.2009del; p.Cys670Serfs*14 variant), 
was the only patient in our cohort who did not present with cardiomyopathy. 
Interestingly, five patients from a consanguineous Arabic family harboring another 
homozygous ELAC2 mutation involving the same consensus splice site (homozygous 
c.1423+2T>A) predominantly presented with intellectual disability without prominent 
cardiac involvement (Akawi et al., 2016). Both of these variants affect the same 
consensus donor sequence (exon 15), and it would be interesting to further explore the 
features of pre-mRNA splice site selection of this particular donor site in cardiac 
tissue. Interestingly, mtDNA depletion was detected in the hypertrophic heart and not 
the skeletal muscle of P7 (Santorelli et al., 2002). To the best of our knowledge, 
quantitative abnormalities of the mtDNA has so far never been associated with 
defects in mtRNA processing, and additional observations are necessary to confirm 
this association. 
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4.2 |Enzymatic mechanism of ELAC2 
The results of our in vitro analysis of the ELAC2 mutants could be used to design 
further experiments aimed at better understanding the enzymology of this 
mitochondrial RNase Z. In particular, the p.Pro493Leu and p.Tyr729Cys substitutions 
most severely impaired enzyme function, resulting in ~1% of WT enzyme activity. 
No mutations were found which interfere directly with metal ion binding or catalysis, 
although numerous such substitutions, constructed by site directed mutagenesis, 
greatly impair catalysis, between 500 – 10,000-fold relative to WT (Karkashon, 
Hopkinson, & Levinger, 2007; Zareen, Yan, Hopkinson, & Levinger, 2005). 
Relatively severe impairment by substitutions of the Pro493 and Tyr729 residues 
probably arises from their proximity in loops to the charged residues that clamp the 
substrate acceptor stem close to the scissile bond. Replacement of proline with 
leucine, although similar in hydrophobicity, could alter the path of the PxKxRN loop, 
affecting the position and orientation of Lys495. With substitution of Tyr729 for Cys 
in the motif V loop, the reduced side chain size could affect the path of the loop, 
including the position and orientation of neighboring Arg728, the arginine residue 
which makes critical polar contacts with the acceptor stem of the substrate. In this 
way the most severe impairment arises from proximity to conserved residues with 
established functions. In this context, our study of naturally occurring pathogenic 
mutations provides further insights and indicates paths for further investigations into 
the enzymatic mechanism of ELAC2. 
4.3 | Missense variant associated with prostate cancer impairs ELAC2 enzymatic 
activity on mitochondrial substrates  
The p.Ala541Thr and p.Arg781His ELAC2 substitutions were first characterized as 
variants in a pedigree in Utah displaying early-onset prostate and other cancers 
(Tavtigian et al., 2001). The appearance of the frequent ELAC2 polymorphism 
p.Ala541Thr in P1 of this study appears to be coincidental and without biological 
significance, as p.Pro493Leu and p.Arg68Trp have been documented here as 
responsible for pathogenicity. The independent reappearance of the missense 
substitution p.Arg781His in P3, P4 and P10, which is exceedingly rare in the general 
population (MAF= 0.0005165 in gnomAD), is here shown to be significant in the 
context of mitochondrial tRNA metabolism. In previously published data, no 
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differences in catalysis were observed between wild type and prostate cancer-
associated mutants of ELAC2 (the missense substitution and two much more frequent 
polymorphisms) using nuclear-encoded pre-tRNA substrates (Minagawa, Takaku, 
Takagi, & Nashimoto, 2005; Takaku, Minagawa, Takagi, & Nashimoto, 2003) (Yan 
and Levinger, unpublished observations). The p.Arg781His substitution, which here 
re-emerged in three described cases of HCM (Patients 3, 4 and 10), clearly impairs 
processing of mitochondrial pre-tRNA substrates both in vitro and in living cells, 
suggesting that the associated phenotypes (possibly including prostate cancer 
susceptibility) are mitochondrially-based.  
Catalytic efficiencies with WT enzyme are generally lower using mitochondrial 
substrates than with nuclear-encoded substrates and the lower catalytic efficiency is 
more pronounced with mt-tRNAIle than with mt-tRNALeu(UUR). Two levels of catalytic 
activity were thus observed, between nuclear vs. mitochondrial and further among 
different mitochondrial tRNAs (Levinger & Serjanov, 2012; Yan et al., 2006). To 
explain the first level distinction, mitochondrial tRNAs generally have a weaker and 
non-canonical secondary and tertiary structure (reviewed in (Florentz, Sohm, Tryoen-
Toth, Putz, & Sissler, 2003)). For example, mt-tRNALeu(UUR) displays a heterogeneous 
secondary structure and among mitochondrial tRNAs, it is closer to canonical than 
mt-tRNAIle, which displays AU rich stems including an A/C mismatch in the T-stem 
(Levinger, Morl, & Florentz, 2004). Wild type substrate structures that reduce wild 
type ELAC2 catalytic efficiencies may thus lead to more pronounced impairment with 
missense substitutions which otherwise were not observed with more canonical 
nuclear encoded substrates. 
4.4 | Conclusions 
Pathogenic variants in ELAC2 impair the RNase Z activity of this critical 
mitochondrial enzyme. Decreased ELAC2 activity leads to a disturbance of proper 
mitochondrial gene expression by increasing the amounts of incorrectly processed 
mtRNA. The consequence of perturbed ELAC2 function is manifested by multiple 
mitochondrial respiratory chain deficiencies, hypertrophic cardiomyopathy and lactic 
acidosis. Therefore, the ELAC2 gene should be included in gene panels to screen 
infantile-onset cases of hypertrophic cardiomyopathy patients. The association 
between the c.2342G>A (p.Arg781His) ELAC2 variant and prostate cancer as a 
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consequence of impaired mitochondrial RNase Z activity could indicate a functional 
link between tumorigenesis and mitochondrial RNA metabolism. 
ACKNOWLEDGMENTS  
C.A.P., P.R-G. and M.M. were supported by Medical Research Council, UK 
(MC_U105697135 and MC_UU_00015/4). P. R.-G. is supported by Fundação para a 
Ciência e a Tecnologia (PD/BD/105750/2014). M.S., M.P., K-G. P. and L.L. were 
supported by the grant R15GM101620 from the NIH. L.L. is a member of the 
graduate programs in Biochemistry and Molecular and Cellular Biology, The City 
University of New York. R.M. and R.W.T. are supported by the Wellcome Centre for 
Mitochondrial Research (203105/Z/16/Z), the MRC Centre for Neuromuscular 
Diseases (G0601943), Newcastle University Centre for Ageing and Vitality 
(supported by the Biotechnology and Biological Sciences Research Council and 
Medical Research Council (G016354/1)), the UK NIHR Biomedical Research Centre 
in Age and Age Related Diseases award to the Newcastle upon Tyne Hospitals NHS 
Foundation, the MRC/ESPRC Newcastle Molecular Pathology Node, the Lily 
Foundation and the UK National Health Service Highly Specialised Service for Rare 
Mitochondrial Disorders. C.L.A. was supported by a National Institute for Health 
Research (NIHR) doctoral fellowship (NIHR-HCS-D12-03-04). R.H. is a Wellcome 
Investigator (109915/Z/15/Z), who receives support from the Medical Research 
Council (UK) (MR/N025431/1), the European Research Council (309548), the 
Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund 
(UK/Turkey, MR/N027302/1). A.A. receives funding for a PhD studentship from the 
Kuwait Civil Service Commission under the approval of the Kuwait Ministry of 
Health. D.G. was supported by the Telethon Foundation (Grant GGP15041); the 
Pierfranco and Luisa Mariani Foundation; the E-Rare project GENOMIT. H.P. was 
supported by the German Bundesministerium für Bildung und Forschung (BMBF) 
and Horizon2020 through the E-Rare project GENOMIT (01GM1603 and 
01GM1207), through the German Network for mitochondrial disorders (mitoNET, 
01GM1113C) and the EU Horizon2020 Collaborative Research Project SOUND 
(633974). The “Cell lines and DNA Bank of Genetic Movement Disorders and 
Mitochondrial Diseases” of the Telethon Network of Genetic Biobanks (grant 
GTB12001J) and the EuroBioBank Network supplied biological specimens. E.B., 
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
R.C. M.D.N and D.V. are supported by the Italian Ministry of Health Ricerca 
Corrente. S.R. receives grant funding from Great Ormond Street Hospital Children’s 
Charity and the Lily Foundation. The funders had no role in study design, data 
collection and analysis, decision to publish, or preparation of the manuscript. 
AUTHORS CONTRIBUTIONS  
Conceptualization: M.M., L.L, H.P., R.W.T; Formal analysis: M.S., C.A.P., R.K., 
B.L., M.M., L.L, H.P. R.W.T, D.G.; Funding acquisition: M.M., L.L, H.P. R.W.T, 
D.G., E.B., R.H. 
Investigation: M.S., C.A.P., P.R-G., R.K., D.G., F.I., E.L., M.P., K-G. P., A.A. 
H.H.A-B, B.A. C.A.L, D.B., M.D.N, D.V., S.R.; Methodology: M.S., L.L., M.M., 
C.A.P.; Project administration: M.M., L.L, H.P. R.W.T, D.G., E.B., E.H. 
Resources: M.A.D, S.S., P.B., M.A., R.C., A.G., E.H., D.G., S.R., R.H. R.M.; 
Supervision: M.M., L.L, H.P. R.W.T, D.G., E.B., E.H. Validation: M.M., L.L, H.P. 
R.W.T.; Visualization: P.R-G., M.S., C.A.P, L.L., M.M.; Writing—original draft: 
M.M., L.L, R.W.T., R.M. Writing—review & editing: All authors;  
REFERENCES Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., . . . Sunyaev, S. R. (2010). A method and server for predicting damaging missense mutations. Nat Methods, 7(4), 248-249. doi:10.1038/nmeth0410-248 Akawi, N. A., Ben-Salem, S., Hertecant, J., John, A., Pramathan, T., Kizhakkedath, P., . . . Al-Gazali, L. (2016). A homozygous splicing mutation in ELAC2 suggests phenotypic variability including intellectual disability with minimal cardiac involvement. Orphanet J Rare Dis, 11(1), 139. doi:10.1186/s13023-016-0526-8 Alston, C. L., Howard, C., Olahova, M., Hardy, S. A., He, L., Murray, P. G., . . . Taylor, R. W. (2016). A recurrent mitochondrial p.Trp22Arg NDUFB3 variant causes a distinctive facial appearance, short stature and a mild biochemical and clinical phenotype. J Med Genet, 53(9), 634-641. doi:10.1136/jmedgenet-2015-103576 Anderson, S., Bankier, A. T., Barrell, B. G., de Bruijn, M. H., Coulson, A. R., Drouin, J., . . . Young, I. G. (1981). Sequence and organization of the human mitochondrial genome. Nature, 290(5806), 457-465. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7219534 Ardissone, A., Tonduti, D., Legati, A., Lamantea, E., Barone, R., Dorboz, I., . . . Ghezzi, D. (2018). KARS-related diseases: progressive leukoencephalopathy with brainstem and spinal cord calcifications as 
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
new phenotype and a review of literature. Orphanet J Rare Dis, 13(1), 45. doi:10.1186/s13023-018-0788-4 Boczonadi, V., Ricci, G., & Horvath, R. (2018). Mitochondrial DNA transcription and translation: clinical syndromes. Essays Biochem, 62(3), 321-340. doi:10.1042/EBC20170103 Bonnen, P. E., Yarham, J. W., Besse, A., Wu, P., Faqeih, E. A., Al-Asmari, A. M., . . . Taylor, R. W. (2013). Mutations in FBXL4 cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance. Am J 
Hum Genet, 93(3), 471-481. doi:S0002-9297(13)00337-6 [pii] 10.1016/j.ajhg.2013.07.017 Brzezniak, L. K., Bijata, M., Szczesny, R. J., & Stepien, P. P. (2011). Involvement of human ELAC2 gene product in 3' end processing of mitochondrial tRNAs. 
RNA biology, 8(4), 616-626. doi:15393 [pii] 10.4161/rna.8.4.15393 Bykhovskaya, Y., Casas, K., Mengesha, E., Inbal, A., & Fischel-Ghodsian, N. (2004). Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). Am J Hum 
Genet, 74(6), 1303-1308. doi:10.1086/421530 S0002-9297(07)62858-4 [pii] Chakraborty, P. K., Schmitz-Abe, K., Kennedy, E. K., Mamady, H., Naas, T., Durie, D., . . . Fleming, M. D. (2014). Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood, 124, 2867-2871. doi:10.1182/blood-2014-08-591370 D'Souza, A. R., & Minczuk, M. (2018). Mitochondrial transcription and translation: overview. Essays Biochem, 62(3), 309-320. doi:10.1042/EBC20170102 Deutschmann, A. J., Amberger, A., Zavadil, C., Steinbeisser, H., Mayr, J. A., Feichtinger, R. G., . . . Zschocke, J. (2014). Mutation or knock-down of 17beta-hydroxysteroid dehydrogenase type 10 cause loss of MRPP1 and impaired processing of mitochondrial heavy strand transcripts. Hum Mol 
Genet, 23(13), 3618-3628. doi:10.1093/hmg/ddu072 Dubrovsky, E. B., Dubrovskaya, V. A., Levinger, L., Schiffer, S., & Marchfelder, A. (2004). Drosophila RNase Z processes mitochondrial and nuclear pre-tRNA 3' ends in vivo. Nucleic Acids Res, 32(1), 255-262. doi:10.1093/nar/gkh182 32/1/255 [pii] Florentz, C., Sohm, B., Tryoen-Toth, P., Putz, J., & Sissler, M. (2003). Human mitochondrial tRNAs in health and disease. Cell Mol Life Sci, 60(7), 1356-1375. doi:10.1007/s00018-003-2343-1 Frazier, A. E., Thorburn, D. R., & Compton, A. G. (2017). Mitochondrial energy generation disorders: genes, mechanisms and clues to pathology. J Biol 
Chem. doi:10.1074/jbc.R117.809194 
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
Garone, C., D'Souza, A. R., Dallabona, C., Lodi, T., Rebelo-Guiomar, P., Rorbach, J., . . . Minczuk, M. (2017). Defective mitochondrial rRNA methyltransferase MRM2 causes MELAS-like clinical syndrome. Hum Mol Genet, 26(21), 4257-4266. doi:10.1093/hmg/ddx314 Ghezzi, D., Baruffini, E., Haack, T. B., Invernizzi, F., Melchionda, L., Dallabona, C., . . . Zeviani, M. (2012). Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis. Am J Hum Genet, 
90(6), 1079-1087. doi:S0002-9297(12)00214-5 [pii] 10.1016/j.ajhg.2012.04.011 Gotz, A., Tyynismaa, H., Euro, L., Ellonen, P., Hyotylainen, T., Ojala, T., . . . Suomalainen, A. (2011). Exome sequencing identifies mitochondrial alanyl-tRNA synthetase mutations in infantile mitochondrial cardiomyopathy. Am J Hum Genet, 88(5), 635-642. doi:S0002-9297(11)00147-9 [pii] 10.1016/j.ajhg.2011.04.006 Haack, T. B., Kopajtich, R., Freisinger, P., Wieland, T., Rorbach, J., Nicholls, T. J., . . . Prokisch, H. (2013). ELAC2 mutations cause a mitochondrial RNA processing defect associated with hypertrophic cardiomyopathy. Am J 
Hum Genet, 93(2), 211-223. doi:10.1016/j.ajhg.2013.06.006 Hallberg, B. M., & Larsson, N. G. (2014). Making proteins in the powerhouse. Cell 
Metab, 20(2), 226-240. doi:10.1016/j.cmet.2014.07.001 Holzmann, J., Frank, P., Loffler, E., Bennett, K. L., Gerner, C., & Rossmanith, W. (2008). RNase P without RNA: identification and functional reconstitution of the human mitochondrial tRNA processing enzyme. Cell, 135(3), 462-474. doi:S0092-8674(08)01135-5 [pii] 10.1016/j.cell.2008.09.013 Karkashon, S., Hopkinson, A., & Levinger, L. (2007). tRNase Z catalysis and conserved residues on the carboxy side of the His cluster. Biochemistry, 
46(33), 9380-9387. doi:10.1021/bi700578v Kim, Y. A., Kim, Y. M., Lee, Y. J., & Cheon, C. K. (2017). The First Korean case of combined oxidative phosphorylation deficiency-17 diagnosed by clinical and molecular investigation. Korean J Pediatr, 60(12), 408-412. doi:10.3345/kjp.2017.60.12.408 Kopajtich, R., Mayr, J. A., & Prokisch, H. (2017). Analysis of Mitochondrial RNA-Processing Defects in Patient-Derived Tissues by qRT-PCR and RNAseq. 
Methods in molecular biology (Clifton, N J ), 1567, 379-390. doi:10.1007/978-1-4939-6824-4_23 Kopajtich, R., Nicholls, T. J., Rorbach, J., Metodiev, M. D., Freisinger, P., Mandel, H., . . . Prokisch, H. (2014). Mutations in GTPBP3 Cause a Mitochondrial Translation Defect Associated with Hypertrophic Cardiomyopathy, Lactic Acidosis, and Encephalopathy. The American Journal of Human Genetics. doi:10.1016/j.ajhg.2014.10.017 
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
Kremer, L. S., Bader, D. M., Mertes, C., Kopajtich, R., Pichler, G., Iuso, A., . . . Prokisch, H. (2017). Genetic diagnosis of Mendelian disorders via RNA sequencing. Nat Commun, 8, 15824. doi:10.1038/ncomms15824 Lax, N. Z., Alston, C. L., Schon, K., Park, S. M., Krishnakumar, D., He, L., . . . Taylor, R. W. (2015). Neuropathologic Characterization of Pontocerebellar Hypoplasia Type 6 Associated With Cardiomyopathy and Hydrops Fetalis and Severe Multisystem Respiratory Chain Deficiency due to Novel RARS2 Mutations. J Neuropathol Exp Neurol, 74(7), 688-703. doi:10.1097/NEN.0000000000000209 Legati, A., Reyes, A., Nasca, A., Invernizzi, F., Lamantea, E., Tiranti, V., . . . Zeviani, M. (2016). New genes and pathomechanisms in mitochondrial disorders unraveled by NGS technologies. Biochim Biophys Acta, 1857(8), 1326-1335. doi:10.1016/j.bbabio.2016.02.022 Levinger, L., Morl, M., & Florentz, C. (2004). Mitochondrial tRNA 3' end metabolism and human disease. Nucleic Acids Res, 32(18), 5430-5441. doi:10.1093/nar/gkh884 Levinger, L., & Serjanov, D. (2012). Pathogenesis-related mutations in the T-loops of human mitochondrial tRNAs affect 3' end processing and tRNA structure. RNA biology, 9(3), 283-291. doi:10.4161/rna.19025 Lopez Sanchez, M. I., Mercer, T. R., Davies, S. M., Shearwood, A. M., Nygard, K. K., Richman, T. R., . . . Filipovska, A. (2011). RNA processing in human mitochondria. Cell Cycle, 10(17), 2904-2916. doi:17060 [pii] Ma, M., Li de la Sierra-Gallay, I., Lazar, N., Pellegrini, O., Durand, D., Marchfelder, A., . . . van Tilbeurgh, H. (2017). The crystal structure of Trz1, the long form RNase Z from yeast. Nucleic Acids Res, 45(10), 6209-6216. doi:10.1093/nar/gkx216 Metodiev, M. D., Thompson, K., Alston, C. L., Morris, A. A., He, L., Assouline, Z., . . . Taylor, R. W. (2016). Recessive Mutations in TRMT10C Cause Defects in Mitochondrial RNA Processing and Multiple Respiratory Chain Deficiencies. Am J Hum Genet, 98(5), 993-1000. doi:10.1016/j.ajhg.2016.03.010 Minagawa, A., Takaku, H., Takagi, M., & Nashimoto, M. (2005). The missense mutations in the candidate prostate cancer gene ELAC2 do not alter enzymatic properties of its product. Cancer Lett, 222(2), 211-215. doi:10.1016/j.canlet.2004.09.013 Nicholls, T. J., Rorbach, J., & Minczuk, M. (2013). Mitochondria: mitochondrial RNA metabolism and human disease. Int J Biochem Cell Biol, 45(4), 845-849. doi:10.1016/j.biocel.2013.01.005 Ojala, D., Montoya, J., & Attardi, G. (1981). tRNA punctuation model of RNA processing in human mitochondria. Nature, 290(5806), 470-474. 
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7219536 Parikh, S., Karaa, A., Goldstein, A., Ng, Y. S., Gorman, G., Feigenbaum, A., . . . Scaglia, F. (2016). Solid organ transplantation in primary mitochondrial disease: Proceed with caution. Mol Genet Metab, 118(3), 178-184. doi:10.1016/j.ymgme.2016.04.009 Paucar, M., Pajak, A., Freyer, C., Bergendal, A., Dory, M., Laffita-Mesa, J. M., . . . Svenningsson, P. (2018). Chorea, psychosis, acanthocytosis, and prolonged survival associated with ELAC2 mutations. Neurology, 91(15), 710-712. doi:10.1212/WNL.0000000000006320 Pearce, S. F., Rebelo-Guiomar, P., D'Souza, A. R., Powell, C. A., Haute, L. V., & Minczuk, M. (2017). Regulation of Mammalian Mitochondrial Gene Expression: Recent Advances. Trends Biochem Sci. doi:10.1016/j.tibs.2017.02.003 Pearce, S. F., Rorbach, J., Van Haute, L., D'Souza, A. R., Rebelo-Guiomar, P., Powell, C. A., . . . Minczuk, M. (2017). Maturation of selected human mitochondrial tRNAs requires deadenylation. Elife, 6. doi:10.7554/eLife.27596 Pellegrini, O., Li de la Sierra-Gallay, I., Piton, J., Gilet, L., & Condon, C. (2012). Activation of tRNA maturation by downstream uracil residues in B. subtilis. Structure, 20(10), 1769-1777. doi:10.1016/j.str.2012.08.002 Powell, C. A., Kopajtich, R., D'Souza, A. R., Rorbach, J., Kremer, L. S., Husain, R. A., . . . Minczuk, M. (2015). TRMT5 Mutations Cause a Defect in Post-transcriptional Modification of Mitochondrial tRNA Associated with Multiple Respiratory-Chain Deficiencies. Am J Hum Genet, 97(2), 319-328. doi:10.1016/j.ajhg.2015.06.011 Powell, C. A., Nicholls, T. J., & Minczuk, M. (2015). Nuclear-encoded factors involved in post-transcriptional processing and modification of mitochondrial tRNAs in human disease. Front Genet, 6, 79. doi:10.3389/fgene.2015.00079 Rahman, J., & Rahman, S. (2018). Mitochondrial medicine in the omics era. 
Lancet, 391(10139), 2560-2574. doi:10.1016/S0140-6736(18)30727-X Rebelo-Guiomar, P., Powell, C. A., Van Haute, L., & Minczuk, M. (2019). The mammalian mitochondrial epitranscriptome. Biochim Biophys Acta Gene 
Regul Mech, 1862(3), 429-446. doi:10.1016/j.bbagrm.2018.11.005 Rorbach, J., Boesch, P., Gammage, P. A., Nicholls, T. J., Pearce, S. F., Patel, D., . . . Minczuk, M. (2014). MRM2 and MRM3 are involved in biogenesis of the large subunit of the mitochondrial ribosome. Mol Biol Cell, 25(17), 2542-2555. doi:10.1091/mbc.E14-01-0014 
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
Rorbach, J., & Minczuk, M. (2012). The post-transcriptional life of mammalian mitochondrial RNA. Biochem J, 444(3), 357-373. doi:BJ20112208 [pii] 10.1042/BJ20112208 Rossmanith, W. (2011). Localization of human RNase Z isoforms: dual nuclear/mitochondrial targeting of the ELAC2 gene product by alternative translation initiation. PLoS One, 6(4), e19152. doi:10.1371/journal.pone.0019152 PONE-D-11-03323 [pii] Santorelli, F. M., Gagliardi, M. G., Dionisi-Vici, C., Parisi, F., Tessa, A., Carrozzo, R., . . . Bertini, E. (2002). Hypertrophic cardiomyopathy and mtDNA depletion. Successful treatment with heart transplantation. Neuromuscul Disord, 
12(1), 56-59. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11731286 Saoura, M., Pinnock, K., Pujantell-Graell, M., & Levinger, L. (2017). Substitutions in conserved regions preceding and within the linker affect activity and flexibility of tRNase ZL, the long form of tRNase Z. PLoS One, 12(10), e0186277. doi:10.1371/journal.pone.0186277 Schilling, O., Spath, B., Kostelecky, B., Marchfelder, A., Meyer-Klaucke, W., & Vogel, A. (2005). Exosite modules guide substrate recognition in the ZiPD/ElaC protein family. J Biol Chem, 280(18), 17857-17862. doi:10.1074/jbc.M500591200 Shinwari, Z. M. A., Almesned, A., Alakhfash, A., Al-Rashdan, A. M., Faqeih, E., Al-Humaidi, Z., . . . Al-Hassnan, Z. N. (2017). The Phenotype and Outcome of Infantile Cardiomyopathy Caused by a Homozygous ELAC2 Mutation. 
Cardiology, 137(3), 188-192. doi:10.1159/000465516 Siira, S. J., Rossetti, G., Richman, T. R., Perks, K., Ermer, J. A., Kuznetsova, I., . . . Filipovska, A. (2018). Concerted regulation of mitochondrial and nuclear non-coding RNAs by a dual-targeted RNase Z. EMBO Rep, 19(10). doi:10.15252/embr.201846198 Spurdle, A. B., Couch, F. J., Hogervorst, F. B., Radice, P., Sinilnikova, O. M., & Group, I. U. G. V. W. (2008). Prediction and assessment of splicing alterations: implications for clinical testing. Hum Mutat, 29(11), 1304-1313. doi:10.1002/humu.20901 Stenton, S. L., & Prokisch, H. (2018). Advancing genomic approaches to the molecular diagnosis of mitochondrial disease. Essays Biochem. doi:10.1042/EBC20170110 Takaku, H., Minagawa, A., Takagi, M., & Nashimoto, M. (2003). A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease. Nucleic Acids Res, 31(9), 2272-2278. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12711671 
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
Tavtigian, S. V., Simard, J., Teng, D. H., Abtin, V., Baumgard, M., Beck, A., . . . Cannon-Albright, L. A. (2001). A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet, 27(2), 172-180. doi:10.1038/84808 Taylor, R. W., Pyle, A., Griffin, H., Blakely, E. L., Duff, J., He, L., . . . Chinnery, P. F. (2014). Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. JAMA, 
312(1), 68-77. doi:10.1001/jama.2014.7184 Thiers, R. E., & Vallee, B. L. (1957). Distribution of metals in subcellular fractions of rat liver. J Biol Chem, 226(2), 911-920. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/13438880 Trujillano, D., Bertoli-Avella, A. M., Kumar Kandaswamy, K., Weiss, M. E., Koster, J., Marais, A., . . . Abou Jamra, R. (2017). Clinical exome sequencing: results from 2819 samples reflecting 1000 families. Eur J Hum Genet, 25(2), 176-182. doi:10.1038/ejhg.2016.146 Van Haute, L., Dietmann, S., Kremer, L., Hussain, S., Pearce, S. F., Powell, C. A., . . . Minczuk, M. (2016). Deficient methylation and formylation of mt-tRNA(Met) wobble cytosine in a patient carrying mutations in NSUN3. 
Nature communications, 7, 12039. Retrieved from <Go to ISI>://MEDLINE:27356879 Van Haute, L., Pearce, S. F., Powell, C. A., D'Souza, A. R., Nicholls, T. J., & Minczuk, M. (2015). Mitochondrial transcript maturation and its disorders. Journal 
of inherited metabolic disease, 38(4), 655-680. Retrieved from <Go to ISI>://MEDLINE:26016801 Wang, Z., Zheng, J., Zhang, X., Peng, J., Liu, J., & Huang, Y. (2012). Identification and sequence analysis of metazoan tRNA 3'-end processing enzymes tRNase Zs. PLoS One, 7(9), e44264. doi:10.1371/journal.pone.0044264 Wedatilake, Y., Niazi, R., Fassone, E., Powell, C. A., Pearce, S., Plagnol, V., . . . Rahman, S. (2016). TRNT1 deficiency: clinical, biochemical and molecular genetic features. Orphanet J Rare Dis, 11(1), 90. doi:10.1186/s13023-016-0477-0 Yan, H., Zareen, N., & Levinger, L. (2006). Naturally occurring mutations in human mitochondrial pre-tRNASer(UCN) can affect the transfer ribonuclease Z cleavage site, processing kinetics, and substrate secondary structure. J Biol Chem, 281(7), 3926-3935. doi:10.1074/jbc.M509822200 Yarham, J. W., Lamichhane, T. N., Pyle, A., Mattijssen, S., Baruffini, E., Bruni, F., . . . Taylor, R. W. (2014). Defective i6A37 modification of mitochondrial and cytosolic tRNAs results from pathogenic mutations in TRIT1 and its substrate tRNA. Plos Genetics, 10(6), e1004424. doi:10.1371/journal.pgen.1004424 
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
Zareen, N., Yan, H., Hopkinson, A., & Levinger, L. (2005). Residues in the conserved His domain of fruit fly tRNase Z that function in catalysis are not involved in substrate recognition or binding. J Mol Biol, 350(2), 189-199. doi:10.1016/j.jmb.2005.04.073 Zeharia, A., Shaag, A., Pappo, O., Mager-Heckel, A. M., Saada, A., Beinat, M., . . . Elpeleg, O. (2009). Acute infantile liver failure due to mutations in the TRMU gene. Am J Hum Genet, 85(3), 401-407. doi:S0002-9297(09)00347-4 [pii] 10.1016/j.ajhg.2009.08.004 
 
Figures 
Figure 1 | ELAC2 mutations and gene/protein structure  
(A) Gene structure of ELAC2 with known protein domains (as defined in (Saoura et 
al., 2017)) of the gene product and localization of amino acid residues and splice sites 
(variants indicated in blue) affected by mutations. Intronic regions are not drawn to 
scale. (B) Conservation of human ELAC2 amino acid residues affected by mutations 
across Pongo tapanuliensis (Pt), Bos Taurus (Bt), Gallus gallus (Gg) and Danio rerio 
(Dr). For complete sequence alignment including Saccharomyces cerevisiae Trz1 used 
for structure modelling, see Figure S3. 
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Figure 2 | Kinetic parameters of the pathogenic ELAC2 variants 
(A) Kinetic parameters of the previously reported ELAC2 variants (Haack et al., 
2013) with mt-tRNALeu(UUR) substrate. The graph shows kcat/KM value relative to WT 
(e.g. the quotient [kcat mutant]/[kcat WT]). The bars indicate standard error. *, ** above 
the bars indicate p-values with a significance of 0.05 and 0.01, respectively, calculated 
using unpaired t-test. (B) Kinetic parameters of the novel ELAC2 variants with mt-
tRNALeu(UUR) substrate analysed as per (A). (C) Kinetic parameters of selected novel 
ELAC2 variants with mt-tRNAIle substrate analysed as per (A).  
 
Figure 3 | Analysis of unprocessed mitochondrial tRNA-mRNA intermediates 
(A) Linear genetic map of mtDNA (numbering according to RefSeq accession 
number J01415) indicating mt-rRNA (green), mt-mRNA (olive) and mt-tRNA (black). 
Non-coding sequences in white. The mt-tRNAVal-16S rRNA and mt-tRNAMet-ND2 
mRNA junctions are indicated by red brackets. LSP – Light strand promoter. HSP – 
Heavy strand promoter. (B) Northern blot processing analysis of the mt-tRNAVal-16S 
rRNA junction in total RNA samples of control fibroblasts (C1-C3), fibroblasts from 
the previously published cases (57415, 61982, 65937)(Haack et al., 2013) and 
fibroblasts from the patients harboring novel ELAC2 mutations (P1-4, P6-9 and P12). 
(C) Northern blot analysis of the processing of the mt-tRNAMet-ND2 mRNA junction. 
Samples as per (B). Asterisks indicate partially degraded RNA samples that were 
reanalysed in a different blot and presented in the same panel.  
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Figure 4 | ELAC2 substitutions mapped on the structure of Saccharomyces 
cerevisiae RNase Z  
The structure of S. cerevisiae RNase Z (Trz1, PDB#5MTZ) (Ma et al., 2017) is shown 
in cartoon using PyMol. The amino domain, inter-domain linker and carboxy domain 
are colored green, blue and pale green, respectively. Three views are shown to 
effectively visualize all the substitutions. All 13 ELAC2 substitutions (3 published 
previously (Haack et al., 2013), and 10 novel) are shown in all three views. Residues 
are labelled with S. cerevisiae RNase Z numbers and the numbers in brackets are for 
the H. sapiens ELAC2 residues. Some residues are not conserved between S. 
cerevisiae and H. sapiens RNase Z. Residues Arg68, Phe154, Gln388 localised in the 
amino domain are marked in red; Leu422 and Leu423 are in linker (also marked in 
red); Pro493, Thr520, Arg564, Lys660, Arg680, Tyr729, His749, Arg781 are in the 
carboxy domain and indicated in purple. (A) View with amino domain up, carboxy 
domain down and linker behind with the H. sapiens residues Phe154, Leu422, 
Leu423, Lys660, Ala680, Tyr729 and Arg781 labelled. (B) The ELAC2 model is 
rotated with linker on left with the residues Arg68, Gln388 and Arg564 labelled; (C) 
ELAC2 rotated with linker on right and the residues Pro493, Thr520 and His749 
labelled. Note: the residues at Arg68, Phe154 and Gln388 in H. sapiens ELAC2 map 
to the domain interface. 
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Figure 5 | In silico analysis of disease-related ELAC2 substitutions p.Pro493Leu 
and p.Tyr729Cys 
(A) Structure overview of S. cerevisiae Trz1. Amino and carboxy domains and linker 
are colored as in previous figures. Curved arrow indicates the presumed substrate 
trough. Metal ions which mark the active site are shown as blue spheres. PxKxRN and 
Motif V loops are shown in magenta and orange, respectively. (B) Detailed view of 
PxKxRN loop (magenta) and Motif V loop (orange) in S. cerevisiae Trz1. The 
conserved basic residues Lys in the PxKxRN loop and Arg in the Motif V loop are 
shown as sticks, with H. sapiens equivalent residues given in brackets. Red arc 
illustrates path of substrate acceptor stem and 3’ trailer through the presumed substrate 
trough. (C) Detailed view of PxKxRN loop (magenta) and Motif V loop (orange) in B. 
subtillis with pre-tRNA substrate (Note: The B. subtillis structure displays similar 
folds and relative orientations, validating its use for modelling ELAC2 (RNase ZL) 
structure including the carboxy domain and the active site. The B. subtilis RNase Z 
structure 4GCW (Pellegrini et al., 2012) is the only available structure of an enzyme – 
pre-tRNA substrate complex). The pre-tRNA substrate acceptor stem is clamped by 
polar contacts with K in the PxKxRN loop (Lys495 in H. sapiens, Lys480 in S. 
cerevisiae, Lys15 in B. subtilis) and Arg in the Motif V loop (Arg728 in H. sapiens, 
Arg763 in S. cerevisiae, Arg273 in B. subtilis), illustrated with bold dashed lines. A 
polar substrate acceptor stem clamp consists of Lys15 contacts with 2’ and 3’ O’s of 
ribose +1 and Arg273 contacts with two backbone phosphate O’s on nt 72 and one on 
nt 73. Counterintuitively, the basic R-groups that form the substrate clamp do not 
point toward each other; both are oriented toward the right, but two polar contacts 
extend to the right from Lys15 while three polar contacts by Arg273 extend to the left 
toward substrate. 
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Table 1 | Patient summary 
Case 
No 
cDNA 
(NM_018127.
6) 
Protein 
(NP_060597) 
Identifica
tion Sex 
Age-at-
onset 
Co
urs
e 
Cardio
myop
athy 
MR
C 
defi
cen
cy 
Additi
onal 
clinical 
featur
es 
Pre
viou
sly 
rep
orte
d 
 
#57415 
c.631C>T; 
c.1559C>T 
p.Arg211∗; 
p.Thr520Ile WES male 
3 
months  
Un
kno
wn 
HCM CI 
Psych
omoto
r 
retard
ation, 
mild 
hypoto
nia, 
lactic 
acidos
is, 
sensor
ineural 
hearin
g 
impair
ment, 
hyperi
ntensit
ies in 
basal 
gangli
a at 
age 3 
m  
Haa
ck 
et 
al., 
201
3 
 
#61982 
c.460T>C; 
c.460T>C 
p.Phe154Leu
; 
p.Phe154Leu 
WES female 
2 
months  
dea
th 
at 
11 
mo
nth
s 
HCM CI 
Intraut
erine 
growth 
retard
ation, 
lactic 
acidos
is, 
cardia
c 
failure; 
norma
l 
muscl
e 
biopsy 
finding
s 
Haa
ck 
et 
al., 
201
3 
 
#65937 
c.1267C>T; 
c.1267C>T 
p.Leu423Phe
; 
p.Leu423Phe 
CGS female 
5 
months 
dea
th 
at 4 
yea
rs 
and 
9 
mo
nth
s 
HCM CI 
Psych
omoto
r 
retard
ation, 
muscu
lar 
hypoto
nia, 
cardia
c 
failure 
Haa
ck 
et 
al., 
201
3 
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 P1 c.1478C>T; c.202C>T p.Pro493Leu; p.Arg68Trp WES female Birth death at 3 we
eks 
HCM CI+CIV 
Lactic 
acidos
is, 
muscl
e 
weakn
ess, 
ragge
d-red 
fibres 
and 
COX-
deficie
nt/SD
H- 
hyper-
reactiv
e 
fibres 
Tayl
or 
et 
al., 
201
4 
P2 c.2009del; c.1423+1G>A 
p.Cys670Serf
s*14; CSM GP male Birth 
aliv
e at 
8 
yea
rs 
No ND 
Lactic 
acidos
is, 
develo
pment
al 
delay, 
ataxia, 
microc
ephaly
, 
consti
pation, 
cereb
ellar 
vermis 
hypopl
asia 
and 
promi
nent 
posteri
or 
fossa 
on 
brain 
MRI 
this 
rep
ort 
P3 
c.297-
2_297delinsT
G; 
c.2342G>A 
CSM; 
p.Arg781His GP 
femal
e 
18 
months 
aliv
e at 
5 
yea
rs 
HCM CI 
Elevat
ed 
blood 
lactate 
level 
(norm
al 
serum 
levels)
, 
develo
pment
al 
delay, 
IUGR 
this 
rep
ort 
P4 c.2186A>G; c.2342G>A 
p.Tyr729Cys; 
p.Arg781His WES 
femal
e 
2 
months 
dea
th 
at 
12 
we
HCM CI 
Lactic 
acidos
is, 
cardio
vascul
this 
rep
ort 
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eks ar 
collap
se  
P5 c.460T>C; c.460T>C 
p.Phe154Leu
; 
p.Phe154Leu 
WES male neonatal 
dea
th 
at 4 
mo
nth
s 
HCM ND 
Lactic 
acidos
is, 
fatal 
infantil
e 
cardio
myopa
thy 
this 
rep
ort 
P6 c.798-1G>T; c.1690C>A  
CSM; 
p.Arg564Ser GP 
femal
e 
4 
months 
dea
th 
at 5 
mo
nth
s 
DCM CI 
Lactic 
acidos
is, 
develo
pment
al 
delay, 
fatal 
infantil
e 
cardio
myopa
thy, 
EF 
30% 
this 
rep
ort 
P7 c.1979A>T; c.2039C>T 
p.Lys660Ile; 
p.Ala680Val WES 
femal
e 
12 
months 
aliv
e at 
24 
yea
rs 
HCM CI+CIV 
Elevat
ed 
blood 
lactate 
level, 
Patien
t 
transpl
anted 
at age 
of 3.8 
years 
Pari
kh 
et 
al., 
201
6 
P8 c.245+2T>A; c.1264C>G 
CSM; 
p.Leu422Val WES 
femal
e 
2 
months 
dea
th 
at 3 
mo
nth
s 
DCM CI 
Lactic 
acidos
is, 
fatal 
infantil
e 
cardio
myopa
thy, 
EF 20-
30% 
this 
rep
ort 
P9 c.1163A>G; c.1163A>G 
p.Gln388Arg; 
p.Gln388Arg GP male 
6 
months 
aliv
e at 
19 
yea
rs 
HCM CI 
Lactic 
acidos
is, 
psych
omoto
r 
retard
ation, 
fatigab
ility, 
periph
eral 
this 
rep
ort 
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neuro
pathy 
P10 c.457delA; c.2342G>A 
p.Ile153Tyrfs
*6; 
p.Arg781His 
WES male 8 months 
aliv
e at 
6 
yea
rs 
HCM CI 
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P11 c.460T>C; c.460T>C 
p.Phe154Leu
; 
p.Phe154Leu 
WES female Birth 
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th 
at 
2.5 
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s 
HCM CI 
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is, 
later 
mild 
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lar 
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nia, 
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e 
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al 
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e 
biopsy 
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P12 
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1delinsT; c. 
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Lactic 
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P13 c.460T>C; c.460T>C 
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; 
p.Phe154Leu 
WES female 
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months 
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th 
at 5 
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Cases reported by Haack et 
al., 2013 are indicated in 
light grey.  
         MRC - Mitochondrial respiratory chain, WES - whole 
exome sequencing, GP -gene panel, CGS - candidate gene 
sequencing 
       CSM - consensus splice mutation; HCM - hypertrophic cardiomyopathy, DCM - 
dilated cardiomyopathy, CI - Complex I, CIV -Complex IV, ND - not determined 
      
Table 2 | Kinetic Parameters of three previously reported pathogenic missense 
mutations in the ELAC2 endonuclease with the pre-mt-tRNALeu(UUR) substrate 
Mutant # 
Trials Mut. / 
WT 
kcat 
(min-1) 
KM 
(nM) 
kcat/KM 
(x 108 M-
1min-1) 
Relative  
kcat * 
Relative 
KM * 
Relative 
kcat/KM * 
WT 11  23.7±2.8 78±8.0 3.2±0.36    
Phe154Leu 4 1 12±2.80 140±36 0.84±0.12 0.51±0.06 1.9±0.53 0.32±0.06 
Leu423Phe 3 2 28±12 79±24 3.3±0.45 0.94±0.11 1.2±0.19 0.79±0.06 
Thr520Ile 4 2 7.8±0.51 8.1±0.19 0.97±0.04 0.39±0.06 1.1±0.16 0.39±0.05 
Column designation, from left: (column 1) Variant: wild-type (WT) or mutant ELAC2. (column 2) 
number of times variant processing experiments were performed. (column 3) The ratio of mutant to WT 
concentration depending on the impairment factor. (columns 4-6) kcat, KM, kcat/KM: values reported are 
means of replicate experiments. Values following ± are standard errors. (columns 7-9) kcat, KM and 
kcat/KM relative to WT (e.g. the quotient [kcat mutant]/[kcat WT]).*Reported variant relative to WT values 
are the means and standard errors for specific experiments performed on the same day, rather than the 
compiled values at the top of the table, therefore differ from results that would be obtained by 
comparing values in columns to the left with aggregate means for WT (first row). Regular font – no 
impairment of enzymatic activity (> 0.8 of WT) or not statistically significant. Italic – mild impairment 
of enzymatic activity (0.8 - 0.2 of WT). 
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Table 3 | Kinetic Parameters of the novel missense mutations in the ELAC2 
endonuclease with the pre-mt-tRNALeu(UUR) substrate 
Mutant # 
Trial
s 
Mut
. / 
WT 
kcat 
(min-1) 
KM 
(nM) 
kcat/KM 
(x 108 M-1min-
1) 
Relative  
kcat 
Relative 
KM 
Relative  
kcat/KM * 
WT 34  20.2±2.1 43±7.7 6.2±0.56    
Arg68Trp 4 4.7 1.9±0.36 37±16 0.81±0.22 0.13±0.032 
0.79±0.2
5 0.20±0.038 
Gln388Ar
g 4 1.9 1.2±0.46 
14±7.
8 1.5±0.66 
0.075±0.0
23 
0.43±0.1
8 0.38±0.17 
Leu422Va
l 3 0.94 9.1 ±3.5 30±15 4.0±1.5 
0.59±0.08
1 1.6±0.39 0.39±0.060 
Pro493Le
u 4 55 
0.09±0.0
2 99±51 
0.014±0.00
35 
0.006±0.0
02 2.0±0.8 0.005±0.002 
Arg564Se
r 4 1.1 
44.1±19.
3 40±27 11±2.8 2.2±0.68 2.5±1.3 1.1±0.16 
Lys660Ile 5 1.8 3.2±1.4 25±10 1.5±0.23 0.23±0.12 1.2±0.54 0.32±0.10 
Ala680Va
l 4 2.2 4.8±1.6 
14±4.
8 4.0±1.2 0.23±0.05 
0.59±0.2
2 0.62±0.24 
Tyr729C
ys 3 82 0.1±0.01 
23±8.
2 
0.056±0.02
2 
0.006±0.0
01 
0.77±0.2
6 
0.0075±0.00
15 
His749Ty
r 6 5.5 1.1±0.12 
23±8.
2 1.1±0.23 0.06±0.01 
0.45±0.1
5 0.18±0.044 
Arg781H
is 3 6.9 7.6±0.70 
131±2
4 0.63±0.14 0.37±0.17 2.9±1.1 0.12±0.013 
Column designation, from left: (column 1) Variant: wild-type (WT) or mutant ELAC2. (column 2) 
Number of times variant processing experiments were performed. (column 3) The ratio of mutant to 
WT concentration depending on the impairment factor. (columns 4-6) kcat, KM, kcat/KM: values reported 
are means of replicate experiments. Values following ± are standard errors. (columns 7-9) kcat, KM and 
kcat/KM relative to WT (e.g. the quotient [kcat mutant]/[kcat WT]). *Reported variant relative to WT values 
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are the means and standard errors for specific experiments performed on the same day, rather than the 
compiled values at the top of the table, therefore differ from results that would be obtained by 
comparing values in columns to the left with aggregate means for WT (first row). Regular font – no 
impairment of enzymatic activity (> 0.8 of WT) or not statistically significant. Italic – mild impairment 
of enzymatic activity (0.8 - 0.2 of WT). Bold – severe impairment of enzymatic activity (< 0.2 of WT). 
 
Table 4 | Kinetic Parameters of the selected novel missense mutations in the 
ELAC2 endonuclease with the pre-mt-tRNAIle substrate 
Mutant 
# 
Trial
s 
Mut
. 
/WT 
kcat 
(min-1) 
KM 
(nM) 
kcat/KM 
(x 108 M-
1min-1) 
Relative  
kcat 
Relativ
e  
KM 
Relative  
kcat/KM * 
WT 3  0.17±0.05 3.4±1.3 0.57±0.17    
Arg564Ser 3 1.1 0.38±0.12 6.5±2.6 0.65±0.10 1.8±0.56 2.8±1.1 0.71±0.11 
Arg781Hi
s 3 6.7 
0.016±0.00
3 
7.1±2.
0 
0.027±0.0
1 
0.20±0.0
4 3.8±1.3 
0.062±0.0
1 
Column designation, from left: (column 1) Variant: wild-type (WT) or mutant ELAC2. (column 2) 
number of times variant processing experiments were performed. (column 3) The ratio of mutant to WT 
concentration depending on the impairment factor. (columns 4-6) kcat, KM, kcat/KM: values reported are 
means of replicate experiments. Values following ± are standard errors. (columns 7-9) kcat, KM and 
kcat/KM relative to WT (e.g. the quotient [kcat mutant]/[kcat WT]). *Reported variant relative to WT values 
are the means and standard errors for specific experiments performed on the same day, rather than the 
compiled values at the top of the table, therefore differ from results that would be obtained by 
comparing values in columns to the left with aggregate means for WT (first row). Regular font – no 
impairment of enzymatic activity (> 0.8 of WT) or not statistically significant. Bold – severe 
impairment of enzymatic activity (< 0.2 of WT). 
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